Certara, a global biosimulation technology-enabled drug development company, has merged its consulting group, Pharsight Consulting Services (PCS), with Quantitative Solutions, a global pharmacometrics consulting company headquartered in Menlo Park, Calif.
This move further strengthens Certara’s position in the burgeoning modeling and simulation/pharmacometric services field, broadening its modeling capabilities, deepening its therapeutic areas of experience and adding new value-added services and clinical outcomes databases. The resulting organization is called Certara Strategic Consulting.
“Certara now offers the broadest array of modeling, simulation and strategic pharmacometric services, from preclinical drug development through post-market approval,” said Edmundo Muniz, M.D., Ph.D., Certara CEO.
Certara Strategic Consulting has a strong presence in the U.S., Canada and Europe and early operations in Japan, Australia and China. Comprised of more than 70 scientists, consultants and industry professionals, Certara Strategic Consulting now can provide the most comprehensive range of outsourced modeling and simulation and strategic pharmacometric services to the global biopharma marketplace.
Certara Strategic Consulting currently serves more than 100 companies worldwide, including large pharmaceutical and established biotech companies, as well as medium and emerging biopharma companies, together with leading nonprofit foundations and regulatory agencies.
This transaction increases Certara’s scientific strength. It broadens the company’s modeling capabilities by adding model-based meta-analysis (MBMA), which uses highly-curated clinical trial data and parametric pharmacology models to increase drug development productivity, quantitatively inform portfolio management, and improve clinical trial success. A unique asset is the clinical outcomes databases for analyzing the comparative effectiveness of a new drug within its competitive landscape. These new offerings enhance Certara’s existing pharmacokinetic/pharmacodynamic (PK/PD) and physiologically-based pharmacokinetic (PBPK) modeling, clinical trial simulation and regulatory writing services.
The merger also deepens Certara’s therapeutic and special population areas of expertise, which include oncology, cardiovascular, orphan/rare diseases, central nervous system, pediatrics, immunology, infectious disease, metabolic and endocrine disease, women’s health, pain, respiratory and ophthalmology.
Certara has four business units: Certara Strategic Consulting, Certara Software, Simcyp (which focuses on PBPK) and Synchrogenix (which specializes in regulatory writing).
Financial details about the transaction have not been disclosed.